Drug Profile
ZD 9063P
Alternative Names: ZD 9063Latest Information Update: 09 Dec 1999
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antineoplastics
- Mechanism of Action Alkylating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Colorectal cancer
Most Recent Events
- 09 Dec 1999 Discontinued-Preclinical for Colorectal cancer in United Kingdom (Unknown route)
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
- 12 Dec 1997 New profile